Regulatory News:
Elekta welcomes investors, analysts and media to an update on its
investments in R&D, with special attention to the Atlantic project: a
magnetic resonance imaging (MRI) guided radiation therapy system.
This event will be held on Thursday, January 22, 2015, from 10:30 –
12:30 CET at University Medical Center (UMC) Utrecht in the Netherlands.
Jan Lagendijk, Professor and Head of Radiation Oncology, Radiology and
Nuclear Medicine Physics at UMC and Marco van Vulpen, Professor of
Radiation Therapy and MRI, also at UMC, will discuss the clinical
relevance of MRI-guided radiation therapy and show the world's first
fully integrated research system, as it nears completion at UMC.
Niklas Savander, Elekta’s President and CEO; Dee Mathieson, Senior Vice
President, Elekta Oncology; and Kevin Brown, Elekta’s Global Vice
President Scientific Research, will talk about Elekta's R&D investments
in general as well as the status of the project and the milestones to
market introduction of the MRI-guided linear accelerator in particular.
Investors, analysts and media who would like to attend, are kindly
requested to give notice by e-mail to elisabeth.natt.och.dag@elekta.com before January
15.
It will also be possible to listen to the presentations over the phone
and via the web. Links and phone numbers will be published in January
2015.
# # #
For further information, please contact: Gert van Santen, Group Vice
President Corporate Communications, Elekta AB Tel: +31 653 561 242,
e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time
Tobias Bülow, Director Financial Communication, Elekta AB Tel:
+46 722 215 017, e-mail: tobias.bulow@elekta.com
Time zone: CET: Central European Time The above information is such that
Elekta AB (publ) shall make public in accordance with the Securities
Market Act and/or the Financial Instruments Trading Act. The information
was published at 15:30 CET on December 22, 2014.
About Elekta
Elekta is a human care company pioneering significant innovations and
clinical solutions for treating cancer and brain disorders. The company
develops sophisticated, state-of-the-art tools and treatment planning
systems for radiation therapy, radiosurgery and brachytherapy, as well
as workflow enhancing software systems across the spectrum of cancer
care. Stretching the boundaries of science and technology, providing
intelligent and resource-efficient solutions that offer confidence to
both health care providers and patients, Elekta aims to improve, prolong
and even save patient lives. Today, Elekta solutions in oncology and
neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs
around 3,800 employees globally. The corporate headquarters is located
in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm.
Website: www.elekta.com.
This information was brought to you by Cision http://news.cision.com
Copyright Business Wire 2014